Follow the money that drives science research in the United States, and more often than not you’ll end up in Washington, D.C. The dollars don’t reach labs on their own, though: Institutions, interest groups, and individuals help legislators decide what to fund — and science competes with every other federal program for resources.
This year scientific research is one of the few areas slated to gain ground in the proposed federal budget, but that budget is not law yet. “If people want to see the research and development funding increase they’re going to need to get up there and say, ‘Look we feel that we need those increases, they’re vital for the future, they’re vital for job creation [and] our future economic competitiveness,'” said Bob Simon, staff director of the Senate Committee on Energy and Natural Resources, at a session of the American Association of the Advancement of Science conference, on Saturday in San Diego, California. Continue reading A Scientist’s Roadmap to Capitol Hill→
A molecular biologist could face a prison sentence for criticizing a report on transgenic gene spread. Ernesto Bustamante Donayre, vice president of the Peruvian College of Biologists, a professional organization, stands accused of defamation, a criminal offense, which in Peru can carry a prison term or fine. What triggered the suit was his public criticism of a report prepared by Antonietta Ornella Gutiérrez Rosati, a biologist at the La Molina National Agricultural University in Lima, identifying a P34S promoter and NK603 and BT11 transgenes in 14 of 42 maize samples from the Barranca region. Continue reading Peruvian GM advocate faces criminal charges→
The offspring of a speed-dating mixer between young scientists and designers is exhibited at London’s Dana Centre this week. On display are prototypes of three designs that communicate the broad themes of energy and recycling, synthetic and systems biology and imaging. The winning entries were selected from the ideas of 30 pairs of graduate students who were introduced at an interdisciplinary speed-dating event in May last year.
See the rest of the review on Nature’s website [html] or as it appeared in print: [pdf]
Britain’s historically strong role in clinical trials seems to be diminishing. Slow returns on drug investment and poor relations between industry and the UK National Health Service (NHS) have been cited as two reasons for this decline.
